223 related articles for article (PubMed ID: 27981563)
1. Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.
Hansen RA; Qian J; Berg RL; Linneman JG; Seoane-Vazquez E; Dutcher S; Raofi S; Page CD; Peissig PL
Clin Pharmacol Ther; 2018 Feb; 103(2):310-317. PubMed ID: 27981563
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.
Hansen RA; Qian J; Berg R; Linneman J; Seoane-Vazquez E; Dutcher SK; Raofi S; Page CD; Peissig P
Pharmacotherapy; 2017 Apr; 37(4):429-437. PubMed ID: 28152215
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly JG; Fischer MA; Kesselheim AS; Gagne JJ
PLoS Med; 2019 Mar; 16(3):e1002763. PubMed ID: 30865626
[TBL] [Abstract][Full Text] [Related]
4. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
[TBL] [Abstract][Full Text] [Related]
5. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
7. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
Das S; Jiang X; Jiang W; Ting TY; Polli JE
Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Database Analysis to Explore Patterns and Economic Burden of Switchback to Brand After Generic or Authorized Generic Utilization.
Alderfer J; Aggarwal J; Gilchrist K; Alvir JMJ; Cook J; Park SH; Stephens JM
Clinicoecon Outcomes Res; 2022; 14():281-291. PubMed ID: 35509961
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of generic versus brand-name antiepileptic medications.
Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
[TBL] [Abstract][Full Text] [Related]
10. Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.
Alatawi Y; Rahman MM; Cheng N; Qian J; Peissig PL; Berg RL; Page CD; Hansen RA
J Clin Pharm Ther; 2018 Jun; 43(3):327-335. PubMed ID: 29092097
[TBL] [Abstract][Full Text] [Related]
11. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
Rathe JØ
Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
[TBL] [Abstract][Full Text] [Related]
12. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
13. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?
Holtkamp M; Theodore WH
Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004
[TBL] [Abstract][Full Text] [Related]
14. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
[TBL] [Abstract][Full Text] [Related]
15. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.
Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J
Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491
[TBL] [Abstract][Full Text] [Related]
16. Did Generic Clopidogrel Commercialization Affect Trends of ER Consultations and Hospitalizations in the Population Treated with Clopidogrel?
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Drugs Aging; 2019 Aug; 36(8):759-768. PubMed ID: 31073846
[TBL] [Abstract][Full Text] [Related]
17. Generic medications for you, but brand-name medications for me.
Keenum AJ; Devoe JE; Chisolm DJ; Wallace LS
Res Social Adm Pharm; 2012; 8(6):574-8. PubMed ID: 22357268
[TBL] [Abstract][Full Text] [Related]
18. Impact of brand or generic labeling on medication effectiveness and side effects.
Faasse K; Martin LR; Grey A; Gamble G; Petrie KJ
Health Psychol; 2016 Feb; 35(2):187-90. PubMed ID: 26462056
[TBL] [Abstract][Full Text] [Related]
19. Exploring factors underlying the attitude of community pharmacists to generic substitution: a nationwide study from Poland.
Drozdowska A; Hermanowski T
Int J Clin Pharm; 2016 Feb; 38(1):162-70. PubMed ID: 26620450
[TBL] [Abstract][Full Text] [Related]
20. Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs.
Cheng N; Rahman MM; Alatawi Y; Qian J; Peissig PL; Berg RL; Page CD; Hansen RA
Drug Saf; 2018 Apr; 41(4):363-376. PubMed ID: 29196989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
